Cargando…
Animal Models for Medications Screening to Treat Addiction /
Annotation
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Cambridge, MA :
Academic Press,
2016.
|
| Colección: | International review of neurobiology ;
v. 126. |
| Temas: | |
| Acceso en línea: | Texto completo Texto completo |
Tabla de Contenidos:
- Front Cover; Animal Models for Medications Screening to Treat Addiction; Copyright; Contents; Contributors; Preface; Chapter One: Considerations in the Evaluation of Potential Efficacy of Medications for Alcohol and Drug Use Disorders: An ... ; 1. Predictive Validity; 2. Methodology; 3. Evaluating Selective Effects; 4. Nonhuman Primates; 5. Cue Effects and Reinstatement; 6. Conclusion; References; Chapter Two: A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction: An Editorial from a Legal Perspective; 1. Introduction.
- 2. The Need for Legislative Incentives for R & D of Dependence Medication2.1. Opiate Dependence and Treatment; 2.1.1. Methadone; 2.1.2. Vivitrol�; 2.1.3. Buprenorphine (Suboxone�); 2.2. Cocaine Dependence and Treatment; 2.3. Methamphetamine Dependence; 3. The Decline of R & D in Pharmaceutical Companies; 3.1. General Trends; 3.2. Reasons for Pharmaceutical Lack of R & D Into Drug Dependence Treatment; 4. Legislation Specifically Incentivizing R & D into Dependence Treatment; 4.1. Market Exclusivity; 4.2. Tax Credit; 4.3. Priority Review Vouchers; 4.4. Advanced Market Commitment.
- 4.5. Liability Reduction4.6. Political Considerations; 5. Conclusion; References; Chapter Three: Identification of Treatment Targets in a Genetic Mouse Model of Voluntary Methamphetamine Drinking; 1. Methamphetamine Actions and Abuse; 2. Overview of Existing MA Medications Studies; 2.1. Dopamine; 2.2. Vesicular Monoamine Transporter 2; 2.3. Gamma-Aminobutyric Acid; 2.4. Cyclic AMP; 2.5. Replacement Therapy and Treating Withdrawal; 2.6. Immunotherapy and Neuroimmune Therapy; 3. Support for the Importance of Genetic Factors in Human Risk for MA Abuse; 3.1. Brain-Derived Neurotrophic Factor.
- 3.2. Dopamine Beta-Hydroxylase3.3. Catechol-O-Methyltransferase; 3.4. Fatty Acid Amide Hydrolase; 3.5. Mu Opioid Receptor; 3.6. Monoamine Oxidase A; 4. Development of Selectively Bred Lines for High and Low MA Intake; 4.1. Existing Behavioral and Physiological Data for the MA Drinking Lines; 4.1.1. Nondrug-Related Behavioral Traits; 4.1.2. Drug Reward-Related Traits; 4.1.3. Drug Aversion-Related Traits; 4.1.4. Locomotor Activation and Sensitization; 4.1.5. Impulsivity; 4.1.6. Circadian Period; 4.1.7. Body Temperature; 4.2. Blood Drug Levels; 4.3. Neurochemical Information.
- 4.4. Genetic Findings and Treatment5. Speculation About Mechanisms and Treatment Targets; Acknowledgments; References; Chapter Four: Screening Medications for the Treatment of Cannabis Use Disorder; 1. Introduction; 2. Animal Models; 3. Findings from Research with Animal Models; 4. Human Laboratory Approaches; 5. Findings from Clinical Trials and Laboratory Studies in Human Volunteers; 6. Conclusion; Acknowledgments; References; Chapter Five: How can we Improve on Modeling Nicotine Addiction to Develop Better Smoking Cessation Treatments?; 1. Introduction; 2. Animal Models.